Page last updated: 2024-10-20

taurine and Recrudescence

taurine has been researched along with Recrudescence in 43 studies

Research Excerpts

ExcerptRelevanceReference
"We believe that peritoneal catheter taurolidine lock could be considered in cases of relapsing or refractory peritonitis, as it could prevent catheter removal and permanent switch to hemodialysis in selected cases, although literature is scarce and further studies are needed."8.02Relapsing peritonitis and taurolidine peritoneal catheter lock: One center experience. ( Álvarez Nadal, M; Burguera Vion, V; Campillo Trapero, C; Fernández Lucas, M; López Melero, E; Rivera Gorrín, ME; Sosa Barrios, RH, 2021)
"Naltrexone and acamprosate may ultimately prove to be useful additions to pharmacotherapy for alcoholism by reducing relapse."4.82Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. ( Littleton, J; Zieglgänsberger, W, 2003)
"We believe that peritoneal catheter taurolidine lock could be considered in cases of relapsing or refractory peritonitis, as it could prevent catheter removal and permanent switch to hemodialysis in selected cases, although literature is scarce and further studies are needed."4.02Relapsing peritonitis and taurolidine peritoneal catheter lock: One center experience. ( Álvarez Nadal, M; Burguera Vion, V; Campillo Trapero, C; Fernández Lucas, M; López Melero, E; Rivera Gorrín, ME; Sosa Barrios, RH, 2021)
"105 patients with severe alcohol dependence, who were treated in 13 centers in Switzerland, took part in this open study."2.70[Acamprosate and psychosocial intervention. An integrative treatment approach for prevention of alcohol dependent patients in Switzerland]. ( Fuchs, WJ; Riebenfeld, D, 2002)
"94 acamprosate-treated and 85 placebo-treated patients completed the treatment phase: of those withdrawn, 104 (52 in each group) relapsed, 69 (33 vs 36, respectively) were lost to follow-up, 63 (31 vs 32) refused to continue treatment, 16 (15 vs 11) had concurrent illness, three (two vs one) died, ten (six vs four) had adverse side-effects, one (acamprosate treated) received the wrong medication, and three (placebo treated) were non-compliant."2.68Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. ( Fischer, F; Fleischhacker, WW; Lesch, OM; Nimmerrichter, A; Oberbauer, H; Platz, T; Potgieter, A; Walter, H; Whitworth, AB, 1996)
"Acamprosate proved to be a safe and effective aid in treating alcohol-dependent patients and in maintaining the abstinence of patients during 2 years."2.68Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. ( Mann, K; Sass, H; Soyka, M; Zieglgänsberger, W, 1996)
"Acamprosate is a newly registered drug that appears to reduce alcohol-drinking in both animal models and clinical conditions."2.68Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. ( Gavrilovic, M; Le Bon, O; Lehert, P; Lion, K; Pelc, I; Verbanck, P, 1997)
"Acamprosate was associated with a reduction in risk of discontinuing treatment for Europe (RR = 0."2.52The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. ( Donoghue, K; Drummond, C; Elzerbi, C; Pilling, S; Saunders, R; Whittington, C, 2015)
"Globally, alcohol abuse and dependence are significant contributors to chronic disease and injury and are responsible for nearly 4% of all deaths annually."2.50The development of acamprosate as a treatment against alcohol relapse. ( Kufahl, PR; Olive, MF; Watterson, LR, 2014)
"Relapse prevention for alcohol dependence has traditionally involved psychosocial and psychotherapeutic interventions."2.43Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention. ( Jung, YC; Namkoong, K, 2006)
"Acamprosate is a relatively new drug that appears to be clinically useful in the treatment of alcohol dependence."2.39Acamprosate in alcohol dependence: how does it work? ( Littleton, J, 1995)
"Standard treatment for alcohol abuse may include pharmacotherapy to alleviate withdrawal symptoms followed by psychotherapy in inpatient and/or outpatient settings."2.39The pharmacological treatment of alcohol dependence: needs and possibilities. ( Mann, K, 1996)
"Treatment with neramexane that shares part of the pharmacological effects of acamprosate on NMDA receptors, however, resulted in a nonselective reduction of lever responding."1.33The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. ( Bachteler, D; Ciccocioppo, R; Danysz, W; Economidou, D; Spanagel, R, 2005)
"Alcohol relapse is a major problem in the treatment of alcohol abuse and alcoholism."1.31Central nervous system mechanisms in alcohol relapse. ( Le, AD; McBride, WJ; Noronha, A, 2002)

Research

Studies (43)

TimeframeStudies, this research(%)All Research%
pre-19904 (9.30)18.7374
1990's13 (30.23)18.2507
2000's12 (27.91)29.6817
2010's10 (23.26)24.3611
2020's4 (9.30)2.80

Authors

AuthorsStudies
Melugin, PR1
Wu, F1
Munoz, C1
Phensy, A1
Pradhan, G1
Luo, Y1
Nofal, A1
Manepalli, R1
Kroener, S1
Sosa Barrios, RH1
Álvarez Nadal, M1
Burguera Vion, V1
Campillo Trapero, C1
López Melero, E1
Fernández Lucas, M1
Rivera Gorrín, ME1
Lannoy, D1
Janes, A1
Lenne, X1
Neuville, S1
Bourry, J1
Odou, P1
Bruandet, A1
Seguy, D1
Tian, J1
Song, M1
Kaufman, DL1
Nyhuis, PW1
Niederhofer, E1
Scherbaum, N2
Schifano, F1
Bonnet, U1
Dembski, N1
Niederhofer, A1
Specka, M1
Tenbergen, M1
Diamanti, A1
Capriati, T1
Iacono, A1
Stout, RL1
Braciszewski, JM1
Subbaraman, MS1
Kranzler, HR1
O'Malley, SS2
Falk, D1
Kufahl, PR1
Watterson, LR1
Olive, MF2
Donoghue, K1
Elzerbi, C1
Saunders, R1
Whittington, C1
Pilling, S1
Drummond, C1
Saitz, R1
Witkiewitz, K1
Vowles, KE1
McCallion, E1
Frohe, T1
Kirouac, M1
Maisto, SA1
Kiefer, F3
Witt, SH1
Frank, J1
Richter, A1
Treutlein, J1
Lemenager, T1
Nöthen, MM1
Cichon, S1
Batra, A1
Berner, M1
Wodarz, N1
Zimmermann, US1
Spanagel, R4
Wiedemann, K2
Smolka, MN1
Heinz, A2
Rietschel, M1
Mann, K4
Wölwer, W1
Frommann, N1
Jänner, M1
Franke, PE1
Lieb, B1
Falkai, P1
Wobrock, T1
Kuhlmann, T1
Radermacher, M1
Maier, W1
Schütz, C2
Ohmann, C1
Burtscheidt, W1
Gaebel, W1
Bujarski, S1
Lunny, K1
Ray, LA1
O'Brien, CP1
Littleton, J2
Zieglgänsberger, W4
Bachteler, D1
Economidou, D1
Danysz, W1
Ciccocioppo, R1
Jahn, H1
Otte, C1
Demiralay, C1
Wolf, K1
Croissant, B1
Diehl, A2
Klein, O2
Zambrano, S1
Nakovics, H1
Jung, YC1
Namkoong, K1
Jiménez-Arriero, MA1
Rubio, G1
Bowers, MS1
Chen, BT1
Chou, JK1
Osborne, MP1
Gass, JT1
See, RE1
Bonci, A1
Janak, PH1
Whitworth, AB1
Fischer, F1
Lesch, OM1
Nimmerrichter, A1
Oberbauer, H1
Platz, T1
Potgieter, A1
Walter, H1
Fleischhacker, WW1
Sass, H1
Soyka, M2
Kotter, G1
Preuss, U1
Pelc, I2
Verbanck, P1
Le Bon, O1
Gavrilovic, M1
Lion, K1
Lehert, P1
Kratzer, U1
Schmidt, WJ1
Sillaber, I1
Corrigall, WA1
Stewart, J1
Shaham, Y1
Schädlich, PK1
Brecht, JG1
Malerich, JA1
Oberpichler-Schwenk, H1
Yarborough, WH1
McBride, WJ1
Le, AD1
Noronha, A1
Fuchs, WJ1
Riebenfeld, D1
Zawadziński, S1
Benke, G1
Eluszkiewicz, S1
Wasikowski, A1
Zarek, S1
Lhuintre, JP1
Daoust, M1
Moore, ND1
Chretien, P1
Saligaut, C1
Tran, G1
Bosimare, F1
Hillemand, B1
Bijleveld, CM1
Vonk, RJ1
Kuipers, F1
Havinga, R1
Fernandes, J1
Bergamini, L1
Mutani, R1
Delsedime, M1
Durelli, L1
Admirand, WH1
Earnest, DL1
Williams, HE1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pilot Study of Combined Treatment for Veterans With Chronic Pain & Opiate Misuse[NCT02423772]37 participants (Actual)Interventional2014-08-31Completed
Augment in Treatment-resistent Obsessive-compulsive Disorder: an Open-label Trial[NCT00590642]30 participants (Anticipated)Observational2006-04-30Completed
Campral (Acamprosate) Treatment of Alcohol Dependence in a Family Medicine Setting: A Randomized, Double-Blind Placebo-Controlled Study[NCT00381043]Phase 4100 participants (Actual)Interventional2006-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

% Compliant With Medication

% of individuals with evidence for 80% compliance with medication based on returned blister packs and weekly diaries. (NCT00381043)
Timeframe: 12 weeks

Interventionpercentage of participants (Number)
1- Acamprosate93.3
2 - Sugar Pill - Placebo91.6

% Dropout

Percentage of participants who dropped out of study by drug condition (NCT00381043)
Timeframe: 12 weeks

Interventionpercentage of participants (Number)
1- Acamprosate21.5
2 - Sugar Pill - Placebo16.3

% Heavy Drinking Days During Trial

% of Heavy drinking days (5 or more drinks/d for a man or 4 or more drinks/d for a woman) over the 12 weeks of the trial. (NCT00381043)
Timeframe: 12 weeks

Interventionpercentage of heavy drinking days (Mean)
1- Acamprosate15.8
2 - Sugar Pill - Placebo18.4

Clinical Global Impression Scale

Range of overall severity of illness: 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill (NCT00381043)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
1- Acamprosate2.3
2 - Sugar Pill - Placebo2.4

Percent Days Abstinent

%Days without any alcohol consumption over the treatment period (NCT00381043)
Timeframe: 12 weeks

Interventionpercentage of days (Mean)
1- Acamprosate40.7
2 - Sugar Pill - Placebo41.6

Percent With Complete Abstinence

% of subjects with no drinking during the 12 week treatment trial (NCT00381043)
Timeframe: 12 weeks

Interventionpercentage of participants (Number)
1- Acamprosate5.9
2 - Sugar Pill - Placebo19.1

Retention

Number of individuals retained in the trial by acamprosate vs placebo group (NCT00381043)
Timeframe: 12 weeks

Interventionparticipants (Number)
1- Acamprosate39
2 - Sugar Pill - Placebo41

Reviews

10 reviews available for taurine and Recrudescence

ArticleYear
The development of acamprosate as a treatment against alcohol relapse.
    Expert opinion on drug discovery, 2014, Volume: 9, Issue:11

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Humans; Recurrence; Taurine

2014
The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
    Addiction (Abingdon, England), 2015, Volume: 110, Issue:6

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Europe; Female; Global Health; Humans; Male; Mid

2015
Research advances in the understanding and treatment of addiction.
    The American journal on addictions, 2003, Volume: 12, Issue:s2

    Topics: Acamprosate; Alcohol Deterrents; Brain; Chronic Disease; Disease Progression; Humans; Naltrexone; Na

2003
Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence.
    The American journal on addictions, 2003, Volume: 12, Issue:s1

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Behavior, Animal; Brain; Humans; Naltrexone; N

2003
Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention.
    Yonsei medical journal, 2006, Apr-30, Volume: 47, Issue:2

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Disulfiram; gamma-Aminobutyric Acid; Glutamine; Humans;

2006
Acamprosate in alcohol dependence: how does it work?
    Addiction (Abingdon, England), 1995, Volume: 90, Issue:9

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Clinical Trials as Topic; Combined Mo

1995
[Pharmacotherapy of alcoholism].
    Medizinische Monatsschrift fur Pharmazeuten, 1996, Volume: 19, Issue:12

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Dopamine Agents; Hum

1996
Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes.
    Trends in pharmacological sciences, 1997, Volume: 18, Issue:2

    Topics: Acamprosate; Alcoholism; Animals; Behavior, Animal; Calcium Channels; Disease Models, Animal; Humans

1997
[Alcoholism: relapse prevention].
    Revue medicale de Bruxelles, 1997, Volume: 18, Issue:4

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Humans; Medical History Taki

1997
The pharmacological treatment of alcohol dependence: needs and possibilities.
    Alcohol and alcoholism (Oxford, Oxfordshire). Supplement, 1996, Volume: 31, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Humans; Recurrence; Taurine

1996

Trials

12 trials available for taurine and Recrudescence

ArticleYear
Effectiveness of Psychoanalytic-Interactional Group Therapy vs. Behavioral Group Therapy in Routine Outpatient Treatment of Alcohol-Dependent Patients.
    Substance use & misuse, 2018, 02-23, Volume: 53, Issue:3

    Topics: Acamprosate; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Disulfiram; Female

2018
What happens when people discontinue taking medications? Lessons from COMBINE.
    Addiction (Abingdon, England), 2014, Volume: 109, Issue:12

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Behavior Therapy; Combined Mod

2014
Pain as a predictor of heavy drinking and any drinking lapses in the COMBINE study and the UK Alcohol Treatment Trial.
    Addiction (Abingdon, England), 2015, Volume: 110, Issue:8

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Behavior Therap

2015
The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: a randomized controlled trial.
    Drug and alcohol dependence, 2011, Nov-01, Volume: 118, Issue:2-3

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Behavior Therapy; Combined Modality Therapy; Cou

2011
The effects of drinking goal on treatment outcome for alcoholism.
    Journal of consulting and clinical psychology, 2013, Volume: 81, Issue:1

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy;

2013
Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
    Journal of psychiatric research, 2005, Volume: 39, Issue:5

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Double-Blind Method; Female; Humans; Leptin; Mal

2005
A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients.
    Alcoholism, clinical and experimental research, 2006, Volume: 30, Issue:4

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Anticonvulsants; Carbamazepine; Female; Humans;

2006
Comparison of acamprosate and placebo in long-term treatment of alcohol dependence.
    Lancet (London, England), 1996, May-25, Volume: 347, Issue:9013

    Topics: Acamprosate; Adult; Alcoholism; Double-Blind Method; Ethanol; Female; Follow-Up Studies; Humans; Mal

1996
Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence.
    Archives of general psychiatry, 1996, Volume: 53, Issue:8

    Topics: Acamprosate; Adult; Aged; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Follow-Up Studi

1996
Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study.
    The British journal of psychiatry : the journal of mental science, 1997, Volume: 171

    Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Diarrhea; Dose-Response Relati

1997
[Acamprosate and psychosocial intervention. An integrative treatment approach for prevention of alcohol dependent patients in Switzerland].
    Praxis, 2002, Apr-24, Volume: 91, Issue:17

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Female; Humans; Male;

2002
Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics.
    Lancet (London, England), 1985, May-04, Volume: 1, Issue:8436

    Topics: Acamprosate; Adult; Alcoholism; Clinical Trials as Topic; Double-Blind Method; Erythrocyte Indices;

1985

Other Studies

21 other studies available for taurine and Recrudescence

ArticleYear
The effects of acamprosate on prefrontal cortical function are mimicked by CaCl2 and they are influenced by the history of alcohol exposure.
    Neuropharmacology, 2022, 07-01, Volume: 212

    Topics: Acamprosate; Animals; Calcium; Calcium Chloride; Ethanol; Mice; Prefrontal Cortex; Recurrence; Tauri

2022
Relapsing peritonitis and taurolidine peritoneal catheter lock: One center experience.
    The journal of vascular access, 2021, Volume: 22, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Catheter-Related Infections; Catheterization;

2021
Cost-effectiveness of taurolidine locks to prevent recurrent catheter-related blood stream infections in adult patients receiving home parenteral nutrition: a 2-year mirror-image study.
    Clinical nutrition (Edinburgh, Scotland), 2021, Volume: 40, Issue:6

    Topics: Adult; Catheter-Related Infections; Catheterization, Central Venous; Central Venous Catheters; Chemo

2021
Homotaurine limits the spreading of T cell autoreactivity within the CNS and ameliorates disease in a model of multiple sclerosis.
    Scientific reports, 2021, 03-08, Volume: 11, Issue:1

    Topics: Animals; Antigen Presentation; Antigen-Presenting Cells; Cell Proliferation; Central Nervous System;

2021
Recurrent catheter related bloodstream infections by Candida glabrata: successful treatment with taurolidine.
    Clinical nutrition (Edinburgh, Scotland), 2014, Volume: 33, Issue:2

    Topics: Anti-Infective Agents; Candida glabrata; Candidiasis; Catheter-Related Infections; Humans; Recurrenc

2014
[Acamprosate and naltrexone: similar efficacy for relapse].
    Revue medicale suisse, 2014, Dec-17, Volume: 10, Issue:455

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Recurrence; T

2014
Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate.
    The pharmacogenomics journal, 2011, Volume: 11, Issue:5

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Alcohols; Atrial Natriuretic Factor; Female; GAT

2011
The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2005, Volume: 30, Issue:6

    Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Animals; Conditioning, Operant; Cues; Cyclopentan

2005
Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone.
    Addiction biology, 2008, Volume: 13, Issue:1

    Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Combined Modality Therapy; Double-Blind Method;

2008
Acamprosate attenuates cocaine- and cue-induced reinstatement of cocaine-seeking behavior in rats.
    Psychopharmacology, 2007, Volume: 195, Issue:3

    Topics: Acamprosate; Alcohol Deterrents; Animals; Behavior, Addictive; Cocaine; Cocaine-Related Disorders; C

2007
The anti-craving drug acamprosate inhibits the conditioned place aversion induced by naloxone-precipitated morphine withdrawal in rats.
    Neuroscience letters, 1998, Aug-07, Volume: 252, Issue:1

    Topics: Acamprosate; Alcohol Deterrents; Analgesics, Opioid; Animals; Conditioning, Psychological; Drug Inte

1998
Acamprosate suppresses the expression of morphine-induced sensitization in rats but does not affect heroin self-administration or relapse induced by heroin or stress.
    Psychopharmacology, 1998, Volume: 139, Issue:4

    Topics: Acamprosate; Animals; Drug Interactions; Drug Tolerance; Food Deprivation; Heroin; Heroin Dependence

1998
The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study.
    PharmacoEconomics, 1998, Volume: 13, Issue:6

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cost-Benefit Analysis; Economics, Pharmaceutical; Germa

1998
Prevention of relapse in alcohol dependence.
    American family physician, 1999, Apr-01, Volume: 59, Issue:7

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior Therapy; Disulfiram; Family; Humans; Naltrexon

1999
[Efficient prevention of relapse with acamprosate].
    Medizinische Monatsschrift fur Pharmazeuten, 2000, Volume: 23, Issue:6

    Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Humans; Recurrence; Taurine

2000
Addiction medicine for the primary care physician.
    The Journal of the Oklahoma State Medical Association, 2001, Volume: 94, Issue:11

    Topics: Acamprosate; Alcohol Deterrents; Alcoholics Anonymous; Alcoholism; Antidepressive Agents, Tricyclic;

2001
Central nervous system mechanisms in alcohol relapse.
    Alcoholism, clinical and experimental research, 2002, Volume: 26, Issue:2

    Topics: Acamprosate; Alcoholism; Animals; Behavior; Central Nervous System; Corticotropin-Releasing Hormone;

2002
["Taurolin-Gel" and Taurolin-Trockengel" in treatment of osseous tissue inflammation].
    Chirurgia narzadow ruchu i ortopedia polska, 1990, Volume: 55, Issue:2

    Topics: Anti-Infective Agents, Local; Chronic Disease; Gels; Humans; Osteitis; Recurrence; Taurine; Thiadiaz

1990
Benign recurrent intrahepatic cholestasis: a long-term follow-up study of two patients.
    Hepatology (Baltimore, Md.), 1989, Volume: 9, Issue:4

    Topics: Bile Acids and Salts; Bilirubin; Calcium Phosphates; Child; Cholestasis, Intrahepatic; Cholestyramin

1989
First clinical experience on the antiepileptic action of taurine.
    European neurology, 1974, Volume: 11, Issue:5

    Topics: Adolescent; Adult; Child; Drug Evaluation; Electroencephalography; Epilepsy; Epilepsy, Tonic-Clonic;

1974
Hyperoxaluria and bowel disease.
    Transactions of the Association of American Physicians, 1971, Volume: 84

    Topics: Calcium Metabolism Disorders; Glycolates; Humans; Ileum; Intestinal Diseases; Kidney Calculi; Liver;

1971